Trial Profile

A Phase 2a, Multicenter, Randomized, Double-blind, Vehicle-controlled, Parallel-group Study to Determine the Safety, Tolerability, Pharmacokinetics and Efficacy of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 22 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

27 Nov 2023 According to an Aclaris Therapeutics media release, results from this trial published in the peer-reviewed journal JID Innovations.
08 May 2023 According to an Aclaris Therapeutics media release, company expects topline data in the second half of 2023, rather than mid-year 2023.
08 Jun 2021 According to an Aclaris Therapeutics media release, the company will hold a a conference call and webcast with an accompanying slide presentation on 8th June to discuss trial data.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com